Fidelity led a series C round for haematology and cancer therapy developer Antengene, whose corporate shareholders include Celgene, Taikang, Tigermed and WuXi AppTec.
Antengene, a China-based haematology and oncology drug developer backed by corporates Celgene, Taikang, WuXi AppTec and Tigermed, collected $97m in series C funding yesterday.
Investment and financial services group Fidelity led the round, which included GL Ventures, GIC, Qiming Venture Partners and Boyu Capital along with undisclosed new and existing backers.
Founded in April 2017, Antengene is working on treatments for blood and autoimmune diseases as well as various cancer indications, with a focus on patient needs in China and…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
